Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
about
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerSynthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancerSystemic Chemotherapy in Advanced Pancreatic CancerSystemic treatment for inoperable pancreatic adenocarcinoma: review and updateMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancerRecent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.Therapeutic options for the management of pancreatic cancer.Current and emerging therapies for the treatment of pancreatic cancer.Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.Pancreatic adenocarcinomaThe efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Systemic therapy for metastatic pancreatic adenocarcinoma.Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact.Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experienceMetastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineA multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersEfficacy of systemic therapy in advanced pancreatic carcinoma.Clinical experiences with G17DT in gastrointestinal malignancies.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancerA phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.Pancreatic cancer: a review of recent advances.
P2860
Q24240739-333F651B-E29F-45DA-9E3E-173643D88A21Q24245085-C3732558-A311-456C-B87B-93EB1412077CQ24657439-7B02A460-6D87-4D44-AE0A-67BEB8CD8D40Q26750440-430A70A3-988D-4BD2-80C5-9641595C40EAQ26830913-8348C934-110D-4F94-AF1F-8C74E0CFFACEQ28082919-B43DA502-EB0B-4876-8CCF-280CF101BE74Q33370390-0331CD65-BD3C-4758-B85A-DCCEACB73510Q33378968-6AC33CFA-2B13-4F9F-9F25-D128DDF06C30Q33380084-2A39469C-364F-4323-A523-62B1CCAA8503Q33394729-098CE876-80FF-4432-A0ED-37ED5F0DC186Q33395047-70FF9D76-AC12-4F24-B5BA-C062B157BD90Q33395577-898A35C8-1AF2-47B1-B882-05D96B25BE2FQ33412001-677FFBD6-3F9C-4E01-A41B-1B1BCB20D223Q33428382-9006AEBB-679B-4C41-89AC-50BCE82D904BQ33440500-C83DD779-B661-4C00-9AF4-99EB1C7596D7Q33621256-04C3F183-C824-439B-B848-1F41B7DEE44CQ33632330-F5D88785-625D-4085-A6A1-16B00C0AE068Q33898080-8D3D822B-1E5B-483F-90B9-CAEF2FD2CF0CQ34093776-8C457D91-F8CC-4C0D-B05D-4F89B50DA507Q34129346-AC66BA7D-D469-4156-B5E4-CFD26A256539Q34137350-0A06555E-43C3-4BA1-99FD-26711D96B605Q34140498-03C2C6F0-12F8-4CF0-8393-DD01A8EB81F0Q34226670-221C6BD1-199A-4E55-99FF-864388E740FDQ34313870-E10F1E03-C485-4701-A95E-A8CD16DD6DF4Q34363486-739BB46F-D87A-4EB5-AC43-483619FFF888Q34422252-E270BA7D-F23E-463A-8F50-6710ED5592F0Q34631279-D8E01783-AC3E-4ED1-9ECF-4619750FD0C4Q34818494-53661D95-0530-4DD9-A524-3DF40987ACFDQ35076238-1E734A80-41B2-4DFB-862F-B042C9048109Q35754232-FF4621E3-4580-4A1A-A9D8-A81604B9BF06Q35781556-C1233486-9592-496D-825F-5948899152FEQ36035888-72B1A682-16DD-44C0-8B5B-910DB94357BCQ36072772-5C7BA19D-2A1B-4C1F-A08B-C040EA4D2877Q36084097-B47843B4-6C4A-4F87-99BE-BA750CD26395Q36384541-5D20C067-16C6-4FFC-826E-E612A8B911FDQ36425154-0D195D76-B5B4-446D-85DD-BF7CBB7D0D73Q36448668-DFDFDBFE-50B8-4227-A8A9-FF67AC00747EQ36610441-9BE9EA7A-D145-4247-A1B9-0ECA8897B881Q36614272-C2168B65-9CC8-4199-ADA3-E6EC72AA9170Q36623071-B4F630BF-F48C-4A5E-A96C-09B935A8916F
P2860
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Gemcitabine versus cisplatin, ...... d multicentre phase III trial.
@ast
Gemcitabine versus cisplatin, ...... d multicentre phase III trial.
@en
type
label
Gemcitabine versus cisplatin, ...... d multicentre phase III trial.
@ast
Gemcitabine versus cisplatin, ...... d multicentre phase III trial.
@en
prefLabel
Gemcitabine versus cisplatin, ...... d multicentre phase III trial.
@ast
Gemcitabine versus cisplatin, ...... d multicentre phase III trial.
@en
P2093
P1433
P1476
Gemcitabine versus cisplatin, ...... d multicentre phase III trial.
@en
P2093
Alessandro Zerbi
Carlo Milandri
Carlo Staudacher
Cristina Oliani
Elisa Bonetto
Eugenio Villa
Gabriele Luppi
Gianpaolo Balzano
Laura Galli
Luca Aldrighetti
P304
P356
10.1016/S1470-2045(05)70175-3
P577
2005-06-01T00:00:00Z